Parents' Occupational Exposure Tied to Offspring's Autism Severity
By Lori Solomon HealthDay Reporter

MONDAY, Aug. 18, 2025 -- Several classes of parental occupational exposures are associated with autism spectrum disorder (ASD) severity and several behavioral subscales, according to a study published in the July issue of the International Journal of Hygiene and Environmental Health.
Erin C. McCanlies, Ph.D., from the National Institute for Occupational Safety and Health in Morgantown, West Virginia, and colleagues assessed whether parental occupational exposures affect autism severity risk. Analysis included 532 parents and their children participating in the Childhood Autism Risks from Genetics and the Environment study.
The researchers found that parental occupational exposures to phenols, ethylene oxide, and plastics/polymers were associated with more severe ASD symptoms. Plastics/polymers were especially associated with multiple developmental and behavioral outcomes, including irritability, hyperactivity, poor receptive and visual language, and lower daily living skills. ASD behaviors were associated with several parental occupational exposures (e.g., anesthetic gases, disinfectants, and pharmaceuticals).
"Our findings suggest that parental exposure to certain workplace chemicals during key fetal development periods may influence not just autism likelihood, but also severity and functioning outcomes for children with autism," McCanlies said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-08-19 06:00
Read more

- FDA Picks George Tidmarsh to Head Center for Drug Evaluation and Research
- New Drug May Fight a Deadly Bone Marrow Disorder
- Sleeping Sickness Eliminated in Kenya, WHO Says
- Millions of Backyard Pools Recalled After Drowning Deaths of Nine Children
- College Students With Autism Have Much Greater Rates Of Anxiety, Depression
- Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions